HDAC9 and breast carcinoma: In the context of breast cancer, the use of HDAC inhibitors has shown potential for increasing the susceptibility of cell lines to nucleoside analog therapy by reversing the epigenetic suppression of important drug efflux pumps such as hENT1 and dCK [56].